drugset
drugset / Trial / NCT00667927

Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission

NCT00667927 ↗

Phase 1 Completed 17 enrolled St. Jude Children's Research Hospital
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study proposes to transfer marker genes (detectable genetic traits or segments of DNA that can be identified and tracked) into aliquots of marrow obtained for Bone Marrow Transplant (BTM) in patients in remission of Acute Myelogenous Leukemia (AML).

Timeline

Start
1991-03
Primary completion
1995-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule — —
Background Busulfan Small molecule — —
Background Cyclophosphamide Other / unclassified — —

Indications

acute myeloid leukemia